Biogen Idec and UCB have signed an exclusive agreement under which UCB will commercialize Biogen products in South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan, and both will develop and commercialize products in China.   Biogen Idec will supply UCB with its portfolio of multiple sclerosis (MS) therapies and investigational candidates, including TECFIDERA, FAMPYRA, AVONEX, TYSABRI, PLEGRIDY and Daclizumab High-Yield Process (DAC HYP). The agreement also includes Biogen’s investigat...